1. Home
  2. NEPH vs TENX Comparison

NEPH vs TENX Comparison

Compare NEPH & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nephros Inc.

NEPH

Nephros Inc.

HOLD

Current Price

$5.43

Market Cap

60.0M

Sector

Health Care

ML Signal

HOLD

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

HOLD

Current Price

$10.11

Market Cap

56.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NEPH
TENX
Founded
1997
1967
Country
United States
United States
Employees
31
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
60.0M
56.2M
IPO Year
2004
N/A

Fundamental Metrics

Financial Performance
Metric
NEPH
TENX
Price
$5.43
$10.11
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$6.00
$17.00
AVG Volume (30 Days)
77.9K
116.3K
Earning Date
11-06-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.14
N/A
Revenue
$17,930,000.00
N/A
Revenue This Year
$33.32
N/A
Revenue Next Year
$12.27
N/A
P/E Ratio
$40.69
N/A
Revenue Growth
32.36
N/A
52 Week Low
$1.39
$4.63
52 Week High
$6.42
$9.91

Technical Indicators

Market Signals
Indicator
NEPH
TENX
Relative Strength Index (RSI) 50.82 77.51
Support Level $5.06 $8.76
Resistance Level $5.97 $9.70
Average True Range (ATR) 0.58 0.57
MACD 0.04 0.16
Stochastic Oscillator 38.54 92.76

Price Performance

Historical Comparison
NEPH
TENX

About NEPH Nephros Inc.

Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.

Share on Social Networks: